Wheeler Bio, an innovative contract development and manufacturing organization (CDMO) specializing in process development and cGMP manufacturing of antibody-based therapies, announced the closing of an oversubscribed Series A-1 financing round. The $35 million round was led by Alloy Therapeutics and Echo Investment Capital (Echo), with participation from Mitsubishi Corporation (Americas), Germin8 Ventures, and Russell Westbrook Enterprises.

Wheeler Bio is an innovative biopharmaceutical contract development and manufacturing organization (CDMO) founded by a team of industry experts and strategic investors who believe a high science/high touch CDMO model is needed to enable innovators to advance programs more efficiently.

Through its unique scientific platform Modular CMC, Wheeler Bio revolutionizes the speed of drug development by enabling the rapid advancement of antibody-based therapeutic candidates from discovery into human clinical trials while establishing a robust chemistry, manufacturing, and controls (CMC) package vital for regulatory filings and ongoing cGMP manufacturing. This includes a full complement of integrated services including manufacturability assessments, stable pool and clone development, process and analytical method development, process demonstration, technology transfer and cGMP manufacturing.